The company DNA-Technology » Company News » The innovative development of the company - the nominee of «Prix Galien Russia 2016»



Dear colleagues and partners!

On April 13, 2016 in the framework of the XXIII Russian National Congress "Human and Medicine" «PRIX GALIEN RUSSIA» *symposium took place, and the nominees of in Award 2016 were announced.

We are pleased to announce that the innovative development of a " Comprehensive assessment of the microbiota and the local inflammation of the reproductive tract of women by real-time PCR ("Femoflor®"+ ImmunoQuantex”), authors - team of doctors and scientists of FSBI "Research Center for Obstetrics, Gynecology and Perinatology" Ministry of Healthcare of the Russian Federation and the “DNA-Technology, Research&Production, LLC”, research directors- Doctor of Medical Sciences, professor Prilepskaya V.N. and Doctor of Biological Sciences, professor Trofimov D. Y, was nominated for a prestigious medical award «Galien Russia - Research in Russia." This award is for companies, institutions, groups of researchers conducting the research work that has had a significant impact on the diagnosis, prevention and treatment of diseases, has made a significant contribution to improving the quality of life of patients in Russia in terms of efficiency, safety, benefits and innovation (
We congratulate all the employees, partners and customers of the "DNA-Technology" company on this significant event! more...

The Prix Galien award was created in 1970 by French pharmacist Roland Mehl for popularization of outstanding advances in pharmacological studies. Since its introduction Prix Galien award has become an event the importance of which is recognized among everyone, who is interested in medical research, including government agencies, scientists, pharmaceutical companies and press in the field of Medicine and Biology. For the same reason, Prix Galien is considered one of the most prestigious international awards in practical medicine and a high award in the field of biological and pharmaceutical research. The first medals of Prix Galien Russia were awarded in the framework of a solemn ceremony in Moscow on October 24, 2013.


Prix Galien – is not only the award, but it is movement towards searching and encouragement of scientific innovations, contributing to health of mankind. We think globally, and our contribution to medicine is quite palpable. This is reflected, among other things, in a constructive partnership with commercial research companies and institutions working in the field of science, politics, finance, R&D and the media.
Our ultimate goal – is successful innovations, where finance, knowledge and skills obtained from different sources, combine to give the opportunity to promote the idea "from and to" for the benefit of patients around the world.

Innovations. The jury consisting of scientists assesses the innovation properties of processes and how the latter are able to improve the welfare of mankind. Marketing and promotion of products, and etc. are not taken into account.

Independence. We do not receive any fees or sponsorship from candidates, nor from pharmaceutical companies. Jury members works exclusively on a voluntary basis, they do not represent any organization, and do not engage in fundraising.

The international scale. Galien Events are held in more than 18 countries. This is one of the most prestigious international awards for medical companies.

Prix Galien Committee in Russia in 2016 will choose among the candidates in the categories: "Best pharmaceutical substance" (i.e., a molecule), "Best Biotechnology Product", "Best orphan drug" and "Medical device".
In addition, the Selection Committee of Prix Galien Russia in 2016 introduces «Galien Russia - Research in Russia" - an award for companies, institutions, groups of scientists, which have developed a medical product or are conducting a research program at least for three years in Russia, which had significant impact on the diagnosis, prevention or treatment of diseases. The jury decides on the basis of who has made the most significant contribution to improving the quality of life of patients in Russia in terms of efficacy, safety, and the benefits of innovation and the development of science in Russia.

Based on materials from the official site: